EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY

Noa Krugliak Cleveland iD, Sabyasachi Ghosh, Benjamin Chastek, Tim Bancroft, Ninfa Candela, Tao Fan iD, Kandavadivu Umashankar, David T Rubin

Inflammatory Bowel Diseases · 03.10.2024 · 30 (10) · 1776-1787

DOI: 10.1093/ibd/izad245 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 31.10.2023. Verfasst von Noa Krugliak Cleveland und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Infliximab, Adalimumab, Biological Products, Crohn Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Takeda Pharmaceuticals USA, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and the impact of treatment sequence on outcomes.

Methods

The ROTARY (Real wOrld ouTcomes Across tReatment sequences in inflammatorY bowel disease patients) study was a retrospective, observational cohort study conducted using data from the Optum Clinical Database between January 1, 2012, and February 29, 2020. Adult patients with Crohn’s disease (CD) or ulcerative colitis (UC) who received 2 biologics successively were included. Biologic treatment sequences were analyzed descriptively. Cox proportional hazards models, adjusted for baseline demographics and clinical characteristics, were used to estimate the hazard ratio of switching or discontinuation for each first- and second-line biologic compared with first- and second-line adalimumab, respectively.

Results

In total, 4648 patients with IBD (CD, n = 3008; UC, n = 1640) were identified. Most patients received tumor necrosis factor α antagonist (anti-TNFα) treatment followed by another anti-TNFα treatment or vedolizumab. Vedolizumab and infliximab had 39.4% and 34.6% lower rates of switching or discontinuation than adalimumab, respectively, as first-line biologics in patients with CD and 30.8% and 34.3% lower rates as first-line biologics in patients with UC, respectively. Vedolizumab, infliximab, and ustekinumab had 47.2%, 40.0%, and 43.5% lower rates of switching or discontinuation than adalimumab, respectively, as second-line biologics in CD and 56.5%, 43.0%, and 45.6% lower rates as second-line biologics in patients with UC, respectively.

Conclusions

Although anti-TNFα treatments were most commonly prescribed, the adjusted rates of discontinuation for adalimumab as both a first- and second-line biologic were higher than for vedolizumab, infliximab, or ustekinumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabAdalimumabBiological ProductsCrohn DiseaseHumansMaleFemaleRetrospective StudiesAdultMiddle AgedAntibodies, Monoclonal, HumanizedColitis, UlcerativeGastrointestinal AgentsInflammatory Bowel DiseasesDrug SubstitutionTreatment OutcomeProportional Hazards Models

Stichwörter der Autor:innen

Crohn’s diseasebiologicsinflammatory bowel diseasesequencingulcerative colitis

Substanzen

vedolizumabInfliximabAdalimumabBiological ProductsAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
  • Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA.
  • Optum, Eden Prairie, MN, USA.

ORCID-Profile: Noa Krugliak Cleveland, Tao Fan

Förderung

  • NIDDK NIH HHS
  • Takeda Pharmaceuticals USA, Inc

Zitieren

APA

Krugliak Cleveland, N., Ghosh, S., Chastek, B., Bancroft, T., Candela, N., Fan, T., Umashankar, K., & Rubin, D. T. (2024). Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflammatory Bowel Diseases, 30(10), 1776-1787. https://doi.org/10.1093/ibd/izad245

Vancouver

Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflammatory Bowel Diseases. 2024;30(10):1776-1787. doi:10.1093/ibd/izad245

BibTeX
@article{KrugliakCleveland2024,
  author = {Krugliak Cleveland, Noa and Ghosh, Sabyasachi and Chastek, Benjamin and Bancroft, Tim and Candela, Ninfa and Fan, Tao and Umashankar, Kandavadivu and Rubin, David T},
  title = {Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {10},
  pages = {1776--1787},
  doi = {10.1093/ibd/izad245}
}
Kostenlos starten →